Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of PD-L1 Tumor Expression in Patients With Large-cell Neuroendocrine Carcinoma (NEC) (EPNEC-GFPC 03-2017)

NCT03305133 is registered in ClinicalTrials.gov with Groupe Francais De Pneumo-Cancerologie as lead sponsor.

NCT NCT03305133
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03305133 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of PD-L1 Tumor Expression in Patients With Large-cell Neuroendocrine Carcinoma (NEC) (EPNEC-GFPC 03-2017)
Lead sponsor
Groupe Francais De Pneumo-Cancerologie
Phase
Observational
Overall status
Completed
Start date
September 26, 2017
Completion date
October 30, 2018
Enrollment
86 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

large cell lung cancer, neuroendocrine carcinoma of lung (diagnosis)